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Abstract 
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Objective: To investigate whether white matter microstructural changes can be used as a predictor of worsening of 
motor features or cognitive decline in patients with Parkinson's disease and verify whether white matter microstructural 
longitudinal changes differ between patients with Parkinson’s disease with normal cognition and those with mild 
cognitive impairment.  
Methods: We enrolled 120 newly diagnosed patients with early stage Parkinson’s disease (27 with mild cognitive 
impairment and 93 with normal cognition) along with 48 controls. Participants were part of the Incidence of Cognitive 
Impairment in Cohorts with Longitudinal Evaluation in Parkinson’s disease study and were assessed at baseline and 18 
months later with cognitive, motor tests and diffusion tensor imaging. The relationships between fractional anisotropy 
and mean diffusivity with disease status, cognitive and motor function were investigated. 
Results: At baseline, patients with early stage Parkinson's disease had significantly higher widespread mean diffusivity 
relative to controls, regardless of cognitive status. In patients with Parkinson's disease/mild cognitive impairment, 
higher mean diffusivity was significantly correlated with lower attention and executive function scores. At follow-up 
frontal mean diffusivity increased significantly when comparing patients with Parkinson's disease/mild cognitive 
impairment with those with normal cognition. Baseline mean diffusivity was a significant predictor of worsening of 
motor features in Parkinson's disease.  
Conclusions: Mean diffusivity represents an important correlate of cognitive function and predictor of motor 
impairment in Parkinson's disease: DTI is potentially a useful tool in stratification of patients into clinical trials and to 
monitor the impact of treatment on motor function. 
 
Introduction 
The incidence of dementia is five times greater in patients with Parkinson’s disease (PD) than in the general 
population[1]. Whether dementia is an inevitable event in PD is yet to be established, but 83% of patients have 
dementia if alive at 20 years from onset[2]. Cognitive changes start early in PD with 36% of newly diagnosed patients 
having mild cognitive impairment (PD-MCI)[3], of whom two-thirds develop dementia within four years[4] Elucidating 
the pathophysiological mechanisms underlying cognitive impairment in PD may therefore influence patients’ treatment 
selection and response monitoring early in their illness. 
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White matter lesions correlate with motor and cognitive abnormalities in otherwise healthy elderly individuals, and are 
predicted to contribute to clinical symptoms in PD[5].  Increased volume of white matter lesions has been described in 
PD, especially in those with dementia[6]. Even slight changes in the WM, as identified by diffusion tensor imaging 
(DTI), might contribute to the cognitive decline in PD[7,8]. Diffusion tensor parameters such as mean diffusivity (MD) 
and fractional anisotropy (FA) are established markers of white matter microstructure and can demonstrate subtle 
damage even when clinical structural imaging shows normal appearing white matter[7].  
 
We therefore proposed that white matter change is a major contributor to cognitive decline in PD. Although the 
underlying pathophysiological process of PD dementia is likely to be heterogeneous[9] we have previously shown that 
in the early stages of PD, there are increases in MD even when there is no significant grey matter volume loss[10], 
suggesting that MD may be an early biomarker of this state. Monitoring white matter changes with DTI offers a non-
invasive biomarker which could reflect a mechanism underlying cognitive impairment in PD. We tested the specific 
hypothesis that longitudinal white matter microstructural changes, characterised by decrease in FA and increase in MD, 
are more pronounced among patients with PD-MCI than those with PD who are cognitively normal at baseline. Further, 
we tested whether baseline white matter abnormalities can be used as a predictor of cognitive decline or worsening of 
motor impairment. 
 
Methods 
The study was approved by the Newcastle and North Tyneside Research Ethics Committee and have therefore been 
performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later 
amendments. All participants provided informed consent prior to their inclusion in the study. Participants were selected 
from the Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation in Parkinson’s Disease (ICICLE-
PD) study. The protocol has been described elsewhere[11], but in summary, we recruited 157 newly diagnosed patients 
with idiopathic PD, by United Kingdom PD Brain bank criteria[12], from community and outpatient clinics in 
Newcastle upon Tyne/Gateshead. Unrelated controls (n= 99), aged 45 years and over were recruited from the local 
community. 
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Exclusion criteria were: insufficient knowledge of English; dementia according to Movement Disorder Society (MDS) 
criteria[13] or significant memory impairment as evidenced by a Mini-Mental State Examination (MMSE)[14] score of 
<24 at presentation, drug-induced parkinsonism, progressive supranuclear palsy, multiple system atrophy or 
corticobasal degeneration.  
 
Structured interviews included demographic data, neurologic examination, the Movement Disorders Society Unified PD 
Rating Scale part III (UPDRS-III)[15], Hoehn and Yahr stage[16] and neuropsychological tests covering all cognitive 
domains[17]. Performances on the individual tasks were transformed into z-scores and the average in each cognitive 
domain was calculated[18]. For data that was not normally distributed and could not be transformed appropriately, 
percentiles derived from a normal distribution were used to estimate cut-offs 1 SD (16th percentile), 1.5 SD (7th 
percentile) and 2 SD (2nd percentile), therefore the cut-offs give approximately the correct percentage of people 
impaired. For example, the pentagon score was assessed as 2 (shape includes 10 angles and clear intersection), 1 (two 
intersecting figures, one with five angles) or 0 (less acceptable copy); using corresponding percentiles from the control 
group, participants scoring 1 were classified as having impairment at the 1 SD and 1.5 SD level, and participants 
scoring 0 were classified as having impairment at the 2 SD level [17]. Assessments were completed in an 'on' motor 
state. Clinical phenotypes of tremor dominant (TD) and postural instability/gait disorder (PIGD) were derived from the 
UPDRS scores[19]. PD medications were recorded and levodopa equivalent daily dose was calculated[20]. 
 
Using the MDS Task Force criteria[21], PD-MCI was diagnosed when patients scored 2 SD below normative means on 
at least two cognitive tests either in two different cognitive domains (attention, memory, language, executive and 
visuospatial functions) or two tests in the same domain. The choice of 2 SD cut-off was based on previous studies 
showing it gives greater diagnostic certainty[22] and optimal sensitivity and specificity[23]. As we had only one 
visuospatial test (pentagon copying from the MMSE), to be consistent with our previous studies[24,11], modified level 
II criteria were used. From our cohort of 157 patients with PD, 39 were diagnosed as PD-MCI. Seventy-four 
participants (42 controls, 23 PD-NC and 9 PD-MCI) did not have baseline DTI scans and in two patients (1 PD-NC and 
1 PD-MCI) the baseline DTI scan had technical problems during acquisition. Nine controls had to be excluded as they 
met the criteria for MCI and three patients (1 PD-NC and 2 PD-MCI) were excluded retrospectively as at follow-up 
they were re-diagnosed as non-idiopathic PD. Therefore, the final baseline cohort consisted of 168 participants (48 
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controls, 93 PD-NC and 27 PD-MCI). At follow-up, two participants had died (1 PD-NC and 1 PD-MCI), twenty-nine 
did not complete the assessments (11 controls, 13 PD-NC and 5 PD-MCI), and the scanner had technical problems 
during the follow-up of two consecutive controls.  
 
MRI acquisition  
Participants had baseline and follow-up MRIs on the same 3T Intera Achieva scanner (Philips Medical Systems, 
Eindhoven, The Netherlands) with an eight-channel receiver head coil. A whole brain standard sagittal T1-weighted 
volumetric scan was acquired using a magnetization prepared rapid gradient echo sequence: echo time= 4.6 ms; 
repetition time= 9.6 ms; inversion time= 4.6 ms, flip angle 8 degrees, sensitivity encoding factor= 2; in-plane field of 
view= 240 x 240 mm; slice thickness= 1.2 mm; voxel size= 1.15 x 1.15 mm. DTI acquisitions were based on a two-
dimensional diffusion-weighted, spin-echo, echo planar imaging sequence with 59 slices: Repetition time= 6,100 ms; 
echo time= 70 ms; flip angle= 90 degrees; voxel size= 2.1 x 2.1 mm; slice thickness= 2.1 mm; field of view= 270 x 270 
mm. Diffusion weighting was performed in 64 directions (diffusion b= 1,000 s/mm2) and in six acquisitions without 
diffusion weighting (b= 0 s/mm2). 
 
MRI pre-processing 
Voxel-based analysis of the DTI data was performed using tract-based spatial statistics (TBSS)[25] in FSL 
(www.fmrib.ox.ac.uk/fsl) 5.0.2[26]. The baseline and follow-up total motion index were compared between groups: no 
group differences were demonstrated either at baseline or follow-up (Supplemental Data 1). After brain extraction, eddy 
current-induced distortion and subject movements were corrected using the Eddy FSL toolbox. FA and MD images 
were created by fitting a tensor model to the raw diffusion data. All FA images were aligned in the standard Montreal 
Neurological Institute 152 (MNI152) space using the non-linear registration tool. The mean of all aligned FA images 
was created and thinned to build a mean FA skeleton representing the centres of all tracts common to all image 
volumes. The baseline skeleton was created using all subjects’ baseline images, whereas the longitudinal skeleton 
included the baseline images of only those participants who completed the follow-up and their respective follow-up 
images all-together. Each aligned FA image volume was projected onto the common skeleton by filling the skeleton 
with FA values from the nearest relevant tract center. The resulting data were fed into the voxelwise cross-subject 
statistics. To estimate the WM microstructural change over 18 months for each participant, we subtracted each 
 7 
projected skeletonized FA image at follow-up from their respective baseline image. The difference images were then 
used in our statistical models. The same steps were followed for the MD images. 
 
Data analyses 
Image Analyses: Voxel-wise statistics were applied to the skeletonized FA and MD data using the randomize tool from 
FSL[27], which performed a 5,000 permutation-based testing using threshold-free cluster enhancement (p<0.05), 
corrected for multiple comparisons by using the family-wise error correction. Group differences regarding FA and MD 
at baseline and interval changes at follow-up were tested using General Linear Model. The designs matrix consisted of 
t-contrasts with   age, sex, education, levodopa equivalent daily dose and, when appropriate, scan intervals and disease 
duration as covariates for comparison between disease groups. White matter lesion volume (normalised to whole brain 
volume) was assessed using the method of Firbank et al. [28]. 
Clinical data: ANOVA (F) or two-sample Student's t (t) test were used to compare means between groups. When 
ANOVA disclosed a significant main effect of group, post hoc differences were assessed using post hoc Bonferroni 
multiple-comparison tests. A chi-square test (x2) was used for categorical data comparison. The relationships between 
baseline FA or MD with motor impairment and cognition were tested using multiple linear regression models, where 
baseline cognitive or motor scores were the dependent variables and FA or MD, the independent variables. These 
analyses were controlled for age, sex, education, disease duration and levodopa equivalent daily dose. However, when 
testing if baseline FA or MD were independent predictors of cognitive decline or worsening of motor impairment after 
18 months, the follow-up cognitive or motor scores were used as the dependent variables, and the analyses were also 
controlled for baseline cognitive or motor scores and interval between visits. For all multiple regression analyses, we 
extracted the total brain baseline values of MD and FA using the ‘fslmeants’ tool from the FSL which extracts the 
average timeseries values of all selected voxels. All analyses were performed in STATA version 14.1, all tests were 
two-tailed, significant results are reported at p<0.05.  Due to the high inter-dependency of the FA and MD measures 
and the exploratory nature of this study, we did not apply Bonferroni corrections for multiple testing when investigating 
within group data.  
 
Results 
The baseline analyses were performed on the 168 participants (48 controls, 93 PD-NC and 27 PD-MCI) who completed 
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the clinical assessment and had baseline DTI scans that passed quality control. After a mean of 18.8 (SD 1.6) months, 
135 (35 controls, 79 PD-NC and 21 PD-MCI) participants completed the follow-up clinical assessment and were re-
scanned successfully. The baseline demographics and clinical characteristics of participants are summarized in Table 1.  
 
The sex distribution between groups was not significantly different. Patients with PD-MCI were significantly older than 
patients with PD-NC. Education was significantly different among groups, however, when interrogation with post hoc 
Bonferroni pairwise tests, no significant differences were found. The proportion of WML was not significantly different 
between groups. Disease duration and motor impairment was similar in both groups. In addition, levodopa equivalent 
daily dose intake was not significantly different among groups. Compared to PD-NC, patients with PD-MCI were 
significantly more affected as evidenced by higher Hoehn and Yahr stages. The clinical phenotype distribution was not 
significantly different between the two groups of patients with PD (Table 1). 
 
Baseline diffusion tensor imaging parameters 
Patients with PD-MCI and PD-NC had significantly higher white matter MD compared with controls in widespread 
regions, involving bilaterally the corona radiata, internal and external capsule, corpus callosum, inferior and superior 
fronto-occipital fasciculi, forceps minor, cingula, superior and inferior longitudinal fasciculi (Figure 1). There were no 
significant differences in MD between PD-MCI and PD-NC at baseline. In terms of FA, patients with PD-MCI had 
significant lower FA than controls in posterior aspect of the inferior fronto-occipital fasciculi, superior and inferior 
longitudinal fasciculi, forceps major, corticospinal tracts and cingula (Figure 1). No significant FA differences between 
the remaining groups.  
 
Relationship between baseline diffusion tensor imaging parameters and cognition  
At baseline, among the patients with PD-MCI, higher MD was significantly related to lower attention and executive 
function scores. The relationships between the other cognitive functions or general cognition with FA or MD baseline 
values were not significant among any of the study groups (Table 2).  
 
Relationship between baseline diffusion tensor imaging parameters and motor function 
Within the combined group of PD (PD-NC and PD-MCI), the relationships between baseline motor impairment with 
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FA or MD were not significant (Table 3).  
Regarding the motor phenotypes, there were no significant differences in terms of baseline FA (F(2, 117) 0.03, p 0.972) 
or MD (F(2, 117) 0.82, p 0.443) values.  
 
Longitudinal diffusion tensor imaging parameters 
At follow-up, there were significant changes in both DTI parameters when compared to baseline, with FA decreasing 
and MD increasing significantly. However, compared to PD-NC, the PD-MCI group showed significant MD changes, 
increasing mainly in their frontal regions (Figure 2). All these changes followed a bilateral and symmetric pattern. 
There were no significant differences in the change in MD in the PD groups compared with controls. Similarly, FA 
changes were not significantly different between groups.  
 
Diffusion tensor imaging parameters as predictors of decline in cognition 
At follow-up, 15% (12 out of 79) of PD-NC progressed to MCI and 14% (3 out of 21) of those participants with 
baseline PD-MCI converted to dementia. Lower baseline values of FA were significantly related with greater decline in 
executive function scores among controls. Within the participants with either PD-NC or PD-MCI, MD and FA were not 
significantly related to cognitive scores (Table 4). Among those patients with PD-NC, FA (β (95%CI) 0.001 (-0.007; 
0.009), p 0.787) and MD (β (95%CI) -0.004 (-0.017; 0.010), p 0.605) values were not predictors of progression to MCI. 
 
Diffusion tensor imaging parameters as predictors of decline in motor impairment  
Within the combined group of PD (PD-NC and PD-MCI), higher MD baseline values were significant predictors of 
motor impairment worsening, however, the relationship between baseline FA and motor impairment was not significant 
(Table 3).  
 
Regarding the motor phenotypes, there were no significant differences in terms of longitudinal changes in FA (F(2, 97) 
1.09, p 0.341) or MD (F(2, 97) 1.59, p 0.210) values. 
 
Discussion 
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This study showed that MD is a significant predictor of worsening motor function in early Parkinson’s disease over 18 
months. We also demonstrated that MD differed between patients with Parkinson's disease and controls even soon after 
diagnosis. Furthermore, in patients with PD-MCI, increased mean diffusivity was significantly associated with attention 
and executive function impairments, and frontal MD increased significantly faster when compared to those with PD-
NC.  
 
The current results confirm our principal hypothesis, and reinforce previous cross-sectional observations[18] of greater 
cortical thinning in the frontal and temporal cortices in PD-MCI compared to cognitively normal patients. It suggests 
that both cortical integrity and connectivity of the frontal lobe are vital for successful cognitive function[29]. The focal 
pattern of frontal white matter deterioration in PD-MCI raises the possibility that there is a synergistically detrimental 
effect of disconnection and concurrent cortical atrophy[18]. However, such causality cannot yet be confirmed with our 
current results. Interestingly, both white matter microstructure and cortical thickness differences between the two PD 
sub-groups only became evident after 18 months. 
 
We demonstrated that in early PD-MCI, higher values of MD are associated with lower attention and executive function 
scores. For these analyses we did not correct for multiple testing, however, our weak but significant p-values are 
concordant with the previously published research demonstrating that even slight changes in the white matter might be 
a contributing factor to the Parkinson’s disease dysexecutive syndrome [7]. Therefore by accepting the null hypothesis 
we would most likely be incurring in error type II as it is well known that the Bonferroni's correction is too 
conservative. Our findings support the hypothesis that disruption of prefrontal connections to the basal ganglia, 
represented by white matter microstructural changes are implicated in some of the cognitive features of PD. According 
to the classical “parallel loop” model, homologous circuits connect frontal cortex to basal ganglia and thalamus[30]. 
These circuits are related to motor and oculomotor function, cognition and emotional regulation. Particularly, the 
dorsolateral prefrontal circuit that has been linked with PD, affecting executive function [31],[32]. We failed to 
demonstrate that MD and FA values are predictors of cognitive decline. It may be that 18 months of interval was not 
long enough to demonstrate such relationship.  
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A meta-analyses [33] on diffusion tensor imaging in PD demonstrated that FA and MD values could distinguish 
patients with PD from healthy controls in five regions: the substantia nigra, the corpus callosum, the cingulate and 
temporal cortices, and the corticospinal tracts, the latter, being associated with increased FA and decreased MD, 
suggesting possible brain reorganization. Furthermore, MD values only could differentiate PD from controls in the 
putamen, globus pallidum and internal capsules. We demonstrated that even at early stages of PD, mean diffusivity is 
significantly higher in the corona radiata, internal and external capsules, corpus callosum, inferior and superior fronto-
occipital fasciculi, forceps minor, cingula, superior and inferior longitudinal fasciculi, and FA is reduced in the posterior 
aspect of the inferior fronto-occipital fasciculi, superior and inferior longitudinal fasciculi, forceps major, corticospinal 
tracts and cingula. 
 
Ofori et al. [34] investigated diffusional longitudinal changes within the substantia nigra in Parkinson’s disease using an 
advanced bi-tensor diffusion model and demonstrated that baseline elevated free-water levels in the posterior substantia 
nigra predicted one year worsening of bradykinesia and general cognitive decline. They suggested that the progressive 
increase of free-water levels might be related to the characteristic degeneration of dopaminergic cells in the substantia 
nigra. Our study demonstrated that baseline white matter MD values predicted 18 months worsening of motor 
symptoms. Although we did not specifically measured substantia nigra free water, it is possible that the findings 
observed by Ofori et al. [34] and ours are interconnected phenomena representing deficits of the substantia nigra 
functional connectivity. Few other studies showed significant correlations between motor impairment in PD and 
substantia nigra diffusional changes[35,36,34]. Rae et al. [7] identified correlation between impairment in motor 
function and reduced fractional anisotropy beyond the substantia nigra, in the white matter. Their findings were based 
on a cross-sectional sample and no correlations were found between mean diffusivity and motor features. In our study 
we failed to identify cross-sectional associations between white matter tract microstructure and motor disability, 
however, we demonstrated that baseline increased MD was predictive of worsening of motor symptoms. This suggests 
that direct presynaptic deposition of PD-related neurodegenerative pathologies could lead to axonal degeneration 
impairing structural connectivities. A combined DTI and graph analysis study found alterations in the structural 
connectivity of several motor and non-motor regions present already at an early stage of disease[37].   
 
Given the well-established differences in disease progression according to the different motor phenotypes of PIGD and 
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TD in Parkinson's disease[38], we investigated the relationship between these phenotypes and DTI metrics. No 
significant differences were found at baseline or 18 month later: the longitudinal changes in MD and FA were not 
significantly different according to phenotype. Similar TBSS baseline findings were also previously demonstrated[39], 
however, when probabilistic tractography was used, increased MD was demonstrated in tracts connecting the right 
premotor cortex and right inferior parietal lobule in TD compared to PIGD. Most previous studies that have reported 
FA and MD differences according to clinical phenotypes used tractography or region of interest rather than TBSS[40], 
which is beyond the scope of our study. 
 
The TBSS voxelwise analysis that we applied is an automated observer-independent technique which reduces potential 
bias because it does not require a priori selection of regions of interest. Furthermore, no arbitrary spatial smoothing is 
necessary, minimizing misalignment and misregistration, increasing the sensitivity and interpretability of findings[25]. 
However, as a drawback TBSS has the disadvantage of only providing group comparisons of the DTI parameters at the 
major white matter bundles without much specificity, therefore not informing which regions are connected by 
individual fibre tracts; furthermore, voxels further from tract centres decrease weighting in the average of voxels 
projected to that location, thereby reducing the sensitivity to detect changes in such locations[41]. This potential lack of 
TBSS sensitivity added to the short disease duration of our patients with PD (6.0 +/- 4.6 months) might have impacted 
in our failure to demonstrate baseline differences between the PD-NC and PD-MCI in terms of white matter integrity, 
even though the two patients groups were significantly different in terms of disease severity and cognitive status. The 
cross-sectional study which used the most comparable methodology to ours[8] involving TBSS and grouping patients 
according to formal criteria to diagnose PD-MCI, also found that all PD groups had higher MD values compared to 
controls. However, in contrast, their patients with PD and cognitive impairment had higher MD values than those with 
PD-NC. This might be explained by their patients’ longer disease duration than in our study (5.8 +/- 5.1 years). In line 
with our findings, a longitudinal study[42] demonstrated that PD patients and matched controls exhibited DTI changes 
over time. They suggested that DTI PD-specific changes over one year did not extend beyond the normal age-associated 
change. Unfortunately, among their 19 participants with PD, only four had MCI, precluding subgroup analyses. Another 
longitudinal study using TBSS [43], which followed patients with PD for two years, did not demonstrate any significant 
time or group effects in FA between PD and controls, or between PD-NC and PD-MCI. The small number of 
participants (n 25) will have reduced their power to detect subgroup differences.  
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In our study, white matter lesions were not significantly different between groups. We did not include white matter 
hyperintensity volume as a covariate in our analyses as we do not consider white matter hyperintensities as a 
confounder but part of a spectrum of the white matter changes. Evidence from a large representative population-based 
autopsy driven study [44] has shown that MRI detection of white matter hyperinstenisties is less sensitive than 
pathology and false negative MRIs are associated with milder pathology. Furthermore, the same group [45] showed that 
the prevalence of white matter lesions is as high as 94% regardless of dementia status. Abnormal DTI measures in white 
matter tracts connecting key regions affected by Parkinson’s disease pathology can also be affected by small-vessel 
disease and white matter lesions, thereby making it difficult to disentangle vascular from non-vascular pathological 
processes in Parkinson’s disease and PD-MCI. Our main interest was to characterise the trajectories of DTI metrics in 
Parkinson’s disease irrespective of the pathological process that is contributing to the white matter changes, hence not 
including white matter lesions as a covariate. 
 
Our diffusion imaging protocol prioritized a large number of gradient directions (64), enabling greater angular 
resolution, therefore, a more accurate FA estimation[7]. However, we demonstrated only modest FA differences at 
baseline and did not demonstrate FA changes at follow-up. It may be that fractional anisotropy reduction only occurs 
later in the course of disease progression. Our cohort comprised of newly-diagnosed Parkinson’s disease cases who had 
very short disease duration. It is possible that MD measurements are inherently more sensitive than FA for detecting 
differences in white matter microstructure as MD is more uniform across the brain than FA, and therefore less affected 
by registration errors in relation to voxel size[43]. Furthermore, while MD characterizes the mean diffusion along both 
axonal and radial orientations, revealing how restricted diffusion is within the white matter, FA characterizes diffusion 
in the axonal orientation relative to radial orientations, representing the degree of directional diffusion[7], [46]. If MD is 
sensitive but directionally non-specific, any process leading to white matter microstructural degeneration would cause 
MD to invariably increase, whereas FA provides more specific information as it depends on the underlying arrangement 
of the fibres[46]. Even so, some authors also consider FA to be non-specific because decreases may result from either 
increased radial (perpendicular) diffusivity or reduced axial (parallel) diffusivity[47].  
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This study has some limitations. Firstly, our patients with PD-MCI were significantly older with more advanced disease 
than the PD-NC. Even though we adjusted the analyses for age, this is a potential bias as older patients with PD have a 
faster rate of disease progression than those at younger ages[48]. We, therefore, performed a series of sensitivity 
analyses selecting subsets of older and with more advanced disease patients with PD-NC and found that our results 
remained robust (Table e-1). Secondly, some participants left the study before the second MRI acquisition. As the 
TBSS implementation of its general linear model does not accommodate incomplete datasets, we could not adjust for 
missing data by means or imputation. However, it is unlikely to have significantly influenced our main results, as there 
were no significant differences between those who left the study and those who continued regarding demographics and 
clinical features (Table e-2). Thirdly, the gap between MRI studies was significantly higher among controls, and they 
had the highest drop-out rate. This probably influenced our power to detect significant differences. Finally, it should 
also be noted that PD patients were assessed while taking their medication which might have influenced some aspects 
of cognition[49], but is unlikely to have significantly altered the diffusion metrics[7]. However, in contrast to most 
other studies, we included levodopa equivalent dose in our analyses[20]. 
 
This study with a prospective longitudinal design, allowed us to evaluate white matter microstructure, at baseline and at 
18 months, to assess the potential for DTI in predicting cognitive decline and worsening of motor function. Our results 
are derived from a well-characterized, large cohort of patients with early PD, with and without MCI based on consensus 
MDS criteria. Our images were gathered all at one site and analyzed using a TBSS approach which enables a rather 
unbiased analysis. We demonstrated that WM microstructural changes can differentiate between Parkinson's disease 
and controls even in early stages of disease and MD is associated with attention and executive function impairment in 
PD-MCI. Furthermore, MD is a predictor of future worsening of motor impairment. We also showed that in PD-MCI, 
the frontal mean diffusivity increases significantly more in PD-MCI than in PD without MCI. Our findings support the 
hypothesis that MD represents an important correlate of cognitive function and is a predictor of motor decline in PD. As 
such diffusion tensor imaging is potentially a useful tool in stratification of patients into clinical trials to monitor the 
impact of treatment on motor and cognitive features.  
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Figure Captions 
Figure 1. Differences in baseline mean diffusivity. TBSS: regions at baseline of increased mean diffusivity and reduce 
fractional anisotropy (p <0.05 corrected) A) Increased mean diffusivity between patients with PD-NC and controls B) 
between patients with PD-MCI and controls. C) Reduced fractional anisotropy between patients with PD-MCI and 
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controls. TBSS results are shown overlaid on an MNI152 template and the mean FA skeleton (green). Significantly 
different voxels of increased MD are shown in red shades and those of reduced FA, in blue. Z-coordinates are 
displayed. 
 
Figure 2. Differences in longitudinal mean diffusivity. TBSS: regions at follow-up of increased mean diffusivity 
interval changes (p <0.05 corrected) between patients with PD-MCI compared to those with PD-NC. TBSS results are 
shown overlaid on an MNI152 template and the mean FA skeleton (green). Significantly different voxels of increased 
MD are shown in red shades. Z-coordinates are displayed. 
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Table 1. Baseline demographics and clinical characteristics  
 
 
 
 
Values expressed as mean (SD)  
a ANOVA, Post hoc Bonferroni pairwise tests: b Controls versus PD-NC, c Controls versus PD-MCI, d PD-NC versus 
PD-MCI, e no significant results on pairwise tests 
  
Characteristic 
Control 
(n=48) 
PD-NC 
(n=93) 
PD-MCI 
(n=27) 
Statistic p 
Female, % 40% 34% 30% x2(2)= 0.8 0.671 
Age, years 66.0 (7.9) 64.3 (10.8) 70.5 (8.1) f(2, 165)= 4.3 0.015a, 0.011d 
Education, years 13.7 (3.7) 13.5 (3.8) 11.6 (4.1) f(2, 165)= 3.1 0.046a,e 
Proportion of WML 
0.003 
(0.01) 
0.004 
(0.01) 
0.007 
(0.01) 
f(2, 165)= 1.8 0.174 
Time to follow-up, months 20.0 (1.7) 18.2 (1.3) 19.0 (1.5) 
f(2, 165)= 
20.1 
<0.001a, <0.001b, 
0.033c 
Duration of PD, months - 6.4 (0.5) 5.6 (0.7) t(118)= 0.7 0.466 
UPDRS-III - 25.9 (1.1) 29.2 (2.2) t(118)= 1.4 0.176 
Hoehn and Yahr - 1.9 (0.1) 2.3 (0.1) t(118)= 2.4 0.018 
Levodopa equivalent dose, mg - 
161.0 
(13.7) 
214.0 
(24.9) 
t(118)= 1.8 0.069 
Clinical phenotype, %    x2(2)= 0.4 0.813 
Postural instability/gait 
difficulty 
- 44% 46%   
Tremor dominance - 40% 35%   
Indeterminate - 15% 18%   
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Table 2. Multiple linear regression analyses examining the relationship between fractional 
anisotropy and mean diffusivity with cognitive in patients with early Parkinson’s disease and 
controls†  
Tests 
Baseline test 
scores 
Baseline fractional anisotropy Baseline mean diffusivity 
Mean (SD) β (95%CI) p β (95%CI) (x 103) p 
Controls      
MMSE 
29.35 (0.81) 
8.50 (-5.59; 22.60) 0.230 -5.47 (-15.52; 4.59) 0.279 
Attention 
0.00 (0.80) 
 0.57 (-12.88; 14.03) 0.932  0.10 (-9.51; 9.71) 0.983 
Executive function 
-0.01 (0.70) 
 -7.97 (-19.33; 3.39) 0.164  7.54 (-0.35; 15.42) 0.061 
Language 
0.00 (0.80) 
 3.09 (-11.12; 17.30) 0.663  1.83 (-8.40; 12.06) 0.720 
Memory 
0.00 (0.77) 
 4.88 (-8.52; 18.27) 0.466  -5.88 (-15.35; 3.59) 0.217 
Visuospatial function 
0.00 (1.00) 
 -3.13 (-21.12; 14.86) 0.727  0.42 (-12.48; 13.31) 0.948 
PD-NC 
 
      
MMSE 
28.91 (1.05) -8.47 (-23.37; 6.43) 0.262 4.79 (-4.81; 14.38) 0.324 
Attention 
-0.48 (1.04) 3.14 (-11.27; 17.55) 0.666 2.78 (-6.48; 12.04) 0.552 
Executive function 
-0.43 (0.70) 1.21 (-7.70; 10.12) 0.787 0.68 (-5.04; 6.41) 0.813 
Language 
-0.05 (0.87) -0.49 (-13.25; 12.27) 0.940 5.10 (-3.02; 13.22) 0.215 
Memory 
-0.47 (0.93) 7.84 (-4.58; 20.25) 0.213 -5.48 (-13.35; 2.39) 0.170 
Visuospatial function 
0.12 (0.73) 2.65 (-7.73; 13.03) 0.613 -2.54 (-9.20; 4.12) 0.450 
PD-MCI 
     
MMSE 
27.81 (1.69) 3.66 (-35.53; 42.86) 0.847 -5.35 (-30.53; 19.84) 0.663 
Attention 
-3.23 (2.83) 47.12 (-17.21; 111.45) 0.142 -42.63 (-81.72; -3.54) 0.034 
Executive function 
-1.80 (1.21) 20.68 (-6.29; 47.65) 0.125 -20.43 (-36.26; -4.60) 0.014 
Language 
-0.68 (1.10) -4.26 (-33.13; 24.61) 0.759 11.55 (-6.57; 29.66) 0.196 
Memory 
-2.72 (1.70) 8.12 (-29.76; 45.99) 0.660 -10.20 (-34.29; 13.89) 0.387 
Visuospatial function 
-1.11 (2.54) -39.48 (-100.04; 21.07) 0.189 12.41 (-28.01; 52.83) 0.529 
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Table 3. Multiple linear regression analyses examining the relationship between fractional 
anisotropy and mean diffusivity with motor impairment in patients with early Parkinson’s 
disease  
UPDRS-III β (95%CI) p 
Baseline†   
Fractional anisotropy -3.92 (-129.14; 121.29) 0.951 
Mean diffusivity (x 103) 16.90 (-63.57; 97.38) 0.678 
Follow-up†† 
  
Fractional anisotropy -102.51 (-215.90; 
10.88) 
0.076 
Mean diffusivity (x 103) 
91.31 (16.74; 165.89) 0.017 
† Analyses were controlled for age, sex, education, disease 
duration and levodopa equivalent daily dose.  
†† Analyses were controlled for age, sex, education, disease 
duration, levodopa equivalent daily dose, baseline motor 
scores and interval between visits. 
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Table 4. Multiple regression analyses of fractional anisotropy or mean diffusivity as 
independent predictors of cognitive scores in patients with early Parkinson’s disease and 
controls† 
 
Tests 
Follow-up test scores Baseline fractional anisotropy Baseline mean diffusivity 
Mean (SD) β (95%CI) p β (95%CI) (x 103) p 
Controls      
MMSE 29.83 (0.45) 2.26 (-7.80; 12.32) 0.651 -0.23 (-6.78; 6.33) 0.944 
Attention -0.18 (0.86)  2.12 (-10.84; 15.07) 0.742  2.48 (-5.94; 10.90) 0.553 
Executive function 0.08 (0.63)  10.23 (1.38; 19.07) 0.025  -3.76 (-10.02; 2.50) 0.231 
Language 0.80 (0.63)  -1.92 (-22.36; 18.51) 0.849  0.57 (-12.73; 13.87) 0.931 
Memory -0.33 (0.85)  4.03 (-10.09; 18.15) 0.565  1.08 (-8.33; 10.49) 0.818 
Visuospatial function 0.26 (0.00)  1.59 (-9.63; 12.81) 0.776  -0.41 (-7.73; 6.91) 0.911 
PD-NC        
MMSE 28.95 (1.30)  -2.51 (-20.89; 15.87) 0.786  5.92 (-5.57; 17.40) 0.308 
Attention -0.85 (1.37)  4.05 (-9.70; 17.81) 0.559  -0.57 (-9.32; 8.19) 0.898 
Executive function -0.23 (0.88)  1.56 (-9.96; 13.07) 0.789  -2.09 (-9.39; 5.21) 0.571 
Language 0.03 (0.69)  3.35 (-6.78; 13.49) 0.511  -1.96 (-8.44; 4.52) 0.548 
Memory -0.64 (1.19)  -8.16 (-21.55; 5.23) 0.228  6.73 (-1.56; 15.02) 0.110 
Visuospatial function -0.31 (1.57)  7.92 (-14.57; 30.41) 0.485  1.78 (-12.46; 16.02) 0.804 
PD-MCI        
MMSE 27.00 (1.79)  27.43 (-15.88; 70.74) 0.197  -21.45 (-51.05; 8.16) 0.143 
Attention -3.64 (3.40)  4.64 (-49.77; 59.05) 0.858  -4.18 (-42.65; 34.29) 0.820 
Executive function -1.77 (0.99)  9.79 (-10.54; 30.11) 0.321  -10.29 (-24.03; 3.44) 0.131 
Language -0.60 (1.08)  4.49 (-19.30; 28.27) 0.690  -3.57 (-20.49; 13.35) 0.656 
Memory -2.91 (1.60)  14.53 (-21.53; 50.59) 0.404  -4.73 (-30.95; 21.49) 0.706 
Visuospatial function -3.25 (3.72)  62.76 (-27.61; 153.13) 0.159  -29.54 (-92.55; 33.47) 0.333 
† Each analysis was controlled for baseline test scores, age, sex, education, levodopa equivalent daily dose, disease 
duration and interview interval.  
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